Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
about
Antiangiogenic effects of oridonin.Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay.Monoclonal antibodies against occludin completely prevented hepatitis C virus infection in a mouse model.Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5.
P2860
Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety evaluation ...... -reactive monoclonal antibody.
@en
Efficacy and safety evaluation ...... -reactive monoclonal antibody.
@nl
type
label
Efficacy and safety evaluation ...... -reactive monoclonal antibody.
@en
Efficacy and safety evaluation ...... -reactive monoclonal antibody.
@nl
prefLabel
Efficacy and safety evaluation ...... -reactive monoclonal antibody.
@en
Efficacy and safety evaluation ...... -reactive monoclonal antibody.
@nl
P2093
P2860
P356
P1476
Efficacy and safety evaluation ...... s-reactive monoclonal antibody
@en
P2093
Akihiro Watari
Akiko Ishii-Watabe
Hiroki Kuniyasu
Kiyohito Yagi
Masayoshi Fukasawa
Masuo Kondoh
Minoru Tada
Takefumi Doi
Tomoyuki Hata
Xiangru Li
P2860
P304
P356
10.1002/PRP2.266
P577
2016-09-27T00:00:00Z